⌘K
Loading ticker…
Aptevo Therapeutics Inc · Healthcare · Pharmaceutical Products
As of 2026-06-26, Aptevo Therapeutics Inc (APVO) has a 3-month relative strength percentile of 42 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 32. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.4%, relative volume 0.23×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
42 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
APVO is in a stage 4 downtrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -6.9% / -65.7%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
APVO appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $54K notional.
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $54K |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APVO Jan avg: -8.08% median: -5.51% win: 25% σ: 11.11% n: 4 2022-04-12 → 2026-05-29 | APVO Feb avg: -3.84% median: -3.57% win: 50% σ: 7.89% n: 4 2022-04-12 → 2026-05-29 | APVO Mar avg: -38.15% median: -39.48% win: 0% σ: 26.89% n: 4 2022-04-12 → 2026-05-29 | APVO Apr avg: -28.12% median: -9.36% win: 20% σ: 40.31% n: 5 2022-04-12 → 2026-05-29 | APVO May avg: -13.04% median: 0.27% win: 60% σ: 25.67% n: 5 2022-04-12 → 2026-05-29 | APVO Jun avg: -30.17% median: -28.61% win: 0% σ: 21.48% n: 4 2022-04-12 → 2026-05-29 (current) | APVO Jul avg: 1.14% median: 0.77% win: 50% σ: 25.87% n: 4 2022-04-12 → 2026-05-29 | APVO Aug avg: -29.95% median: -25.98% win: 0% σ: 23.51% n: 4 2022-04-12 → 2026-05-29 | APVO Sep avg: -25.19% median: -19.56% win: 0% σ: 17.57% n: 4 2022-04-12 → 2026-05-29 | APVO Oct avg: 10.36% median: 3.12% win: 50% σ: 28.04% n: 4 2022-04-12 → 2026-05-29 | APVO Nov avg: -9.32% median: -3.83% win: 50% σ: 17.42% n: 4 2022-04-12 → 2026-05-29 | APVO Dec avg: -37.33% median: -42.03% win: 0% σ: 28.02% n: 4 2022-04-12 → 2026-05-29 |